Objective: To investigate the expression of SMAD proteins in human thyroid tissues since the inactivation of TGF-b/activin signaling components is reported in several types of cancer. Phosphorylated SMAD 2 and SMAD3 (pSMAD2/3) associated with the SMAD4 induce the signal transduction generated by TGF-b and activin, while SMAD7 inhibits this intracellular signaling. Although TGF-b and activin exert antiproliferative roles in thyroid follicular cells, thyroid tumors express high levels of these proteins. Materials and methods: The protein expression of SMADs was evaluated in multinodular goiter, follicular adenoma, papillary and follicular carcinomas by immunohistochemistry. Results: The expression of pSMAD2/3, SMAD4 and SMAD7 was observed in both benign and malignant thyroid tumors. Although pSMAD2/3, SMAD4 and SMAD7 exhibited high cytoplasmic staining in carcinomas, the nuclear staining of pSMAD2/3 was not different between benign and malignant lesions. 
T hyroid tumors are the most common neoplasms of the endocrine system (1). They are classified as benign tumors (adenomas and multinodular goiters) and malignant tumors, which are allocated as differentiated (papillary and follicular carcinomas) and poorly differentiated (anaplastic carcinoma) (1) . The thyroid malignant transformation is dependent on molecular alterations that result in a disruption of several intracellular signaling, including the unbalance of TGF-b/ activin inhibitory pathway, by a mechanism not yet clarified (2, 3) .
The TGF-b superfamily is comprised of related proteins including the TGF-bs, activins and bone morphogenetic proteins which affect a wide variety of biological processes, regulating cell proliferation and differentiation, apoptosis and development (4, 5) . TGF-b acts by binding to specific serine/threonine kinase transmembrane receptors, which induce intracellular signaling mediated by SMAD proteins. The receptors complexed to TGF-b phosphorylate and activate the receptor-regulated SMADs (R-SMAD), SMAD2 and SMAD3. The activation of SMAD2/ SMAD3 allows their interaction with common-mediator SMAD (co-SMAD), SMAD4, and then this complex moves to the nucleus where it regulates gene transcription. Although activin binds to its own specific receptors, the same set of SMADs is recruited for its signal transduction (6) (7) (8) (9) (10) . This TGF-b/activin signaling is attenuated by SMAD7, an inhibitory SMAD (I-SMAD) that prevents phosphorylation of SMAD2/3 and interferes with the formation of complex SMAD2/3 and SMAD4 (11, 12) .
TGF-b and activin are proliferation-inhibitory factors for epithelial cells, such as hepatic, intestinal, mammary, pancreatic and prostatic cells including thyroid follicular cells (13) (14) (15) (16) (17) (18) (19) . Although both TGF-b and activin exert inhibitory effects on the proliferation of normal thyroid follicular cells, we have previously reported that thyroid tumors express the TGF-b isoforms, TGFb-1, TGFb-2 and TGFb-3 as well as activin isoforms, activin A and activin B (20, 21 ). An impairment of signal transduction has been identified in the development and progression of several epithelial cancers (17, 22) . Therefore, in this study, we investigated the integrity of TGF-b/activin signaling by analyzing the expression of SMAD2/3, SMAD4 and SMAD7 proteins in thyroid tumors.
MATERIAlS AnD METhODS
We analyzed the expression of SMAD4, phosphorylated SMAD2/3 and SMAD7, in normal and tumoral thyroid tissue by immunohistochemical method.
Paraffin sections from human thyroid of normal tissue (N, n = 12), multinodular goiter (MNG, n = 10), follicular adenoma (FA, n = 5), follicular carcinoma (FC, n = 4) and papillary carcinoma (PC, n = 9), were submitted to deparaffinization in xylene and hydration through a series of decreasing alcohol concentrations. The immunohistochemical procedure was performed by an indirect 3-stage immunoenzymatic method as described previously (23) . Briefly, after endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 15 minutes, tissues were washed in phosphate-buffered saline (PBS) and were incubated with goat polyclonal anti-phosphorylated SMAD2/3 antibody (sc-11769, Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit polyclonal anti-SMAD4 (sc-7154, Santa Cruz Biotechnology) or goat polyclonal anti-SMAD7 antibody (sc-7004, Santa Cruz Biotechnology) overnight. The primary antibodies were diluted at 1:100 in Tris-buffered saline and 0.05% albumin. Between the antibodies incubation the tissues were washed in PBS. After incubation with biotin-streptavidin-peroxidase, the reaction was revealed by a mixture of 3,3'-diaminobenzidine with hydrogen peroxide. The sections were then counterstained with Gill's hematoxylin. The immunopositivity of the reaction was detected as brown staining observed by light microscopy. The intensity of immunostaining of follicular cells was evaluated and classified as weak, moderate and strong. Due to variable intensity of positivity seen even in the same tissue, we considered the staining intensity present in more than 50% of positive cells. The percentage of pSMAD2/3 immunopositive cells was determined by counting 3 areas randomly chosen in the tissue in a total of 900 cells. The percentage of nuclear stained cells for pS-MAD2/3 was also determined.
The negative control was performed omitting the primary antibody (SMAD4) and incubating tissues with primary antibody preabsorbed with corresponding peptide, pSMAD2/3 (sc-11769 P, Santa Cruz Biotechnology) and SMAD7 (sc-7004 P, Santa Cruz Biotechnology) peptides (antibody/peptide: 1/5) overnight.
The statistical analysis was made using the semiquantitative results of immunohistochemical staining. The data are presented as the mean ± standard deviation (SD) and were submitted to analysis of variance 
RESUlTS
The expression pattern of SMADs in the neoplastic cells of papillary carcinoma was predominantly homogeneous and strong. In MNG, heterogeneous positivity of SMADs was observed in the same tissue with a given follicle displaying positive and negative cells. Phosphorylated SMAD2/3 was detected in all tissues, however its expression is stronger in carcinomas (follicular and papillary) (Figure 1 ). The analysis of immunohistochemical staining in the normal and neoplastic tissues is summarized in table 1.
To further investigate the integrity of SMAD signaling in thyroid tumors, we evaluated the percentage of pSMAD2/3 positive cells and the localization of this protein at the subcellular level in thyroid tumor tissues (Figure 2A) . The immunohistochemical analysis of pS-MAD2/3 expression showed that the number of positive cells for pSMAD2/3 was higher in tumoral samples when compared with normal tissue ( Figure 2B ). Immunopositive cells were more abundant in carcinomas and adenomas than in MNG tissues (P < 0.05). When we analyzed the nuclear staining of pSMAD2/3, positivity was about 30% and was similar in MNG, adenoma and carcinoma tissues ( Figure 2B ). We also detected nuclear positivity of SMAD4 in both benign and malignant lesions, whereas the immunostaining of SMAD7 was predominantly cytoplasmic.
DISCUSSIOn
TGF-b and activin exert antiproliferative effects in epithelial cells, including follicular thyroid cells (24) . However, TGF-b and activin are overexpressed in several carcinomas (17, 19, 25) . Similarly, we have previously shown high TGF-b and activin protein expression in thyroid cancer, while the expression in normal tissue is predominantly negative (20, 21) . Despite the increased expression of these proteins in neoplastic cells, loss of TGF-b/activin responsiveness is frequently observed in cancer (2) . In human goiter samples, proliferation was not inhibited in the presence of TGF-b (26), proving that even cells derived from benign lesions became irresponsive to TGF-b. Conversely, we have shown that a papillary thyroid carcinoma cell line is still sensitive to the antiproliferative effect generated distinctly by TGF-b1 and activin, possibly mediated by a functional Smad pathway (27) . SMAD2, SMAD3 and SMAD4 are TGF-b/activin intracellular mediators, representing the stimulatory SMADs of this signaling pathway, while SMAD7 is an inhibitory SMAD for this pathway (6) (7) (8) . In the present study, to verify the integrity of the SMAD pathway, we investigated the expression of SMAD4, pSMAD2/3 and SMAD7 in thyroid tumors. As illustrated in figure 2, SMAD4 and pSMAD2/3 as well as inhibitory SMAD7 are expressed in all of tumoral stages of thyroid from benign to malignant lesions, whereas these proteins are rarely detected in normal thyroid tissue. SMAD proteins mediate antiproliferative SMAD4 is known as DPC4 (deleted in pancreatic carcinoma locus 4) due to high frequency of deletions in the gene encoding SMAD4 found in pancreatic carcinoma. Inactivating mutations or deletions of this gene in others cancers such as colon carcinomas and, more recently, in thyroid tumors, were also reported (28, 33) . Differently from what is observed in pancreatic and colon carcinomas, in our study, SMAD4 was expressed in most thyroid tumors, displaying high expression mainly in the carcinomas.
SMAD7 inhibits the growth arrest and apoptosis induced by TGF-b and activin (34, 35) . The transcription of SMAD7 is induced by either TGF-b or activin representing a negative feedback mechanism of TGF-b/ activin signaling (36) . Unlike SMAD2, SMAD3 and SMAD4, display nuclear translocation induced upon ligand stimulus, SMAD7 accumulates in the cytoplasm upon TGF-b/receptor activation to inhibit signal transduction (37) . Up-regulation of SMAD7 is reported in several carcinomas and is implicated in cancer progression (38) (39) (40) . In thyroid tumor, we detected increased expression of inhibitory SMAD7 in papillary and follicular carcinomas, indicating that SMAD7 may be also involved in thyroid tumorigenesis.
In this study, the presence of nuclear immunopositivity for the stimulatory SMADs, SMAD4 and pS-MAD2/3 indicates that the TGF-b/activin signaling pathway is intact in thyroid tumors. This antiproliferative signaling is critical to limit tumor progression. However, the antiproliferative SMADs signal induced by TGF-b/activin proteins could be attenuated by the high expression of an antagonist SMAD, SMAD7, observed mostly in thyroid carcinomas.
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